StockIQpro
NASDAQ:ARQT

Arcutis Biotherapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Arcutis Biotherapeutics, Inc.'s revenue grew 91.3% in fiscal 2025 to $376.1M while operating margin rose to −3.3%, its highest in 4 years. Free cash flow was −$6.3M, −1.7% of revenue, and the diluted share count rose 5.2%.Summary generated from Arcutis Biotherapeutics, Inc.'s SEC filings. Latest annual report filed Feb 25, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$376.1M
Revenue growth+91.3%
Revenue, 5-yr CAGRn/a
Gross margin90.2%
Operating margin−3.3%
Net margin−4.3%
ROIC−4.3%
Return on equity−9.3%
Debt / equity0.58
Free cash flow−$6.3M
FCF margin−1.7%
Share count change+5.2%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue0460197376
Operating income−207−302−241−128−12
Net income−206−311−262−140−16
Free cash flow−176−258−247−112−6

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations